Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 4Gastrointestinal 4Breast 4Thoracic 3Tumor-Agnostic 2Sarcoma 2Genitourinary 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Dermatologic 1

Conditions

Neoplasms 2

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × saracatinib × Tumor-Agnostic × Clear all
NCT02085603 2018-04-13

SarCaBon

Sheffield Teaching Hospitals NHS Foundation Trust

Phase 2 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT00496028 2010-09-22

Phase I Study in Patients With Solid Tumours

AstraZeneca

Phase 1 Completed
148 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡